<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003302</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066242</org_study_id>
    <secondary_id>UPCC-ACR-6883</secondary_id>
    <nct_id>NCT00003302</nct_id>
  </id_info>
  <brief_title>MRI to Detect Breast Tumors in Women</brief_title>
  <official_title>Breast MRI Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: New imaging procedures, such as MRI, may improve the ability to detect breast
      tumors.

      PURPOSE: Diagnostic study to determine the value of MRI in detecting breast tumors in women
      who have had suspicious mammographic or clinical examinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the performance of breast magnetic resonance imaging (MRI) in
      conjunction with mammography for the detection and characterization of lesions in women with
      suspicious mammographic or clinical examinations. II. Assess the incremental value of breast
      MRI to determine the local extent of cancer in these patients. III. Assess the value of
      breast MRI to determine the prevalence and characteristics of incidental enhancing lesions in
      the remainder of the breast.

      OUTLINE: This is a multicenter study. Patients undergo a high resolution 3D post contrast
      magnetic resonance imaging (MRI) scan. Patients with enhancing abnormalities undergo a
      dynamic scan no less than 18 hours later. Some patients may require a third scan if a core
      biopsy is to be performed. Patients who are ultimately found to have cancer are assessed for
      extent of cancer including measurement of the index lesion and identification of other
      present foci of cancer in relation to the index lesion. Further histological diagnosis of
      index lesions is determined by MRI-guided needle localization excisional biopsy. Patients
      with benign needle biopsy are followed for 2 years. Patients with benign primary lesions
      receive a follow up MRI scan 1 year after the initial scan. Patients with benign primary
      lesions and incidental enhancing lesions (IEL) are followed at 2 years. Patients with
      negative needle biopsies not yielding a specific diagnosis and who do not undergo subsequent
      excisional biopsy are followed yearly for 2 years.

      PROJECTED ACCRUAL: A total of 1500 patients will be accrued for this study over 4.25 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 1998</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiomammography</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Suspicious mammographic finding or palpable abnormality OR
        Suspicious clinical or ultrasound finding without associated benign mammographic features
        May have more than one suspicious lesion based on mammography or clinical exam if an index
        lesion is present Mammogram within 2 months prior to MRI scan and copy of films required of
        all patients 30 years of age and over Eligibility maintained if patient meets above
        criteria and has had: Breast implant Prior benign excisional or core biopsy at least 6
        months prior to study Fine needle aspiration performed at any time Cancer in the
        contralateral breast No history of prior breast cancer in the study breast No benign
        excisional or core biopsy of the affected breast within the last 6 months

        PATIENT CHARACTERISTICS: Age: 18 to 79 Sex: Women Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Cardiovascular: No implanted pacemaker Other: No implanted ferromagnetic device
        No ferromagnetic aneurysm clip No severe claustrophobia No ocular metal fragments No
        schrapnel injury No difficulty lying prone No poor venous access No impaired
        decision-making abilities Not pregnant

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Schnall, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at the University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetskliniken Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universitaet</name>
      <address>
        <city>Halle Saale</city>
        <zip>DOH-0-6112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006 Jan;238(1):42-53.</citation>
    <PMID>16373758</PMID>
  </results_reference>
  <results_reference>
    <citation>Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis CA. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol. 2005 Oct 1;92(1):32-8.</citation>
    <PMID>16180227</PMID>
  </results_reference>
  <results_reference>
    <citation>Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 8;292(22):2735-42.</citation>
    <PMID>15585733</PMID>
  </results_reference>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2004</study_first_posted>
  <last_update_submitted>May 9, 2009</last_update_submitted>
  <last_update_submitted_qc>May 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <keyword>breast cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

